Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ADAMTS1 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS10 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 10 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TREM1 Biologics Sequence Review Report 2026: Triggering receptor expressed on myeloid cells 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TREM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM19 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TREM2 Biologics Sequence Review Report 2026: Triggering receptor expressed on myeloid cells 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TREM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM12 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 12 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8L2 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8-like protein 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8L2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8L1 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8-like protein 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8L1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8L3 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8-like protein 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8L3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP6 Biologics Sequence Review Report 2026: Tumor necrosis factor-inducible gene 6 protein Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
S1PR5 Biologics Sequence Review Report 2026: Sphingosine 1-phosphate receptor 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of S1PR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.